MedTrace Logo

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

NCT03307993 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-04-04

No results posted yet for this study

Summary

To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)

Conditions

Interventions

DRUG

Idalopirdine

Idalopirdine 60-120 mg daily dose

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2018-02-19
Completion
2018-02-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03307993 on ClinicalTrials.gov